SerenaGroup

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, SerenaGroup sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

SerenaGroup: 10 sponsored US clinical trials, 2 recruiting.

SerenaGroup sponsors 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Adult, with 2 trials.

Top-decile sponsor footprint

SerenaGroup ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the SerenaGroup pipeline

2 recruiting of 10 indexed (20% open); 6 completed (60%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Healthy Adult (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

SerenaGroup: open-pipeline peers nationwide

Peers matched on 10 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

SerenaGroup sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40% Total trials Recruiting share SerenaGroupAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAcera SurgicalAlign TechnologyAltruBioAlvernia University
SerenaGroup sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SerenaGroup sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this SerenaGroup page

10 registered trials is a research-attention snapshot, not an endorsement of SerenaGroup or any single study.

  • 2 of SerenaGroup's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy Adult is the condition SerenaGroup studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Adult trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

SerenaGroup pipeline card: 10 registered trials from official public datasets.Report a data error.